E-Mail Alert

Add your e-mail address to receive forthcoming issues of this journal:

Journal Browser

Journal Browser

Special Issue "Targeted Drug Delivery and Nanocarriers"

A special issue of Molecules (ISSN 1420-3049). This special issue belongs to the section "Medicinal Chemistry".

Deadline for manuscript submissions: 10 April 2018

Special Issue Editors

Guest Editor
Prof. Sanjay Garg

School of Pharmacy and Medical Sciences, University of South Australia, Adelaide, Australia
Website | E-Mail
Interests: controlled drug delivery; nanoparticles; targeted therapy; anticancer drug delivery systems; nanotechnology; antibacterials for superbugs; wound healing; veterinary formulations
Guest Editor
Dr. Usha Y Nayak

Department of Pharmaceutics, Manipal College of Pharmaceutical Sciences (MCOPS), Manipal University, Manipal, Karnataka-576104, India
Website | E-Mail
Interests: controlled drug delivery; polymeric nanoparticles; liposomes; nanoemulsions; lipid nanoparticles; chronotherapeutics; solubility enhancement

Special Issue Information

Dear Colleagues,

Nanocarriers are widely explored systems for diagnostic and various drug delivery applications. Among the controlled drug delivery technologies, targeted drug delivery has attracted the attention of researchers, as it comprises the systemic delivery of the drug-carrier system to specific cell types, tissues, or organs. Multifunctional capabilities of nanocarriers make them suitable for the targeted delivery of drugs with diverse nature, including proteins, peptides, or DNA. Polymeric/lipid-based nanoparticles, nanocomposites, nanofibres, and carbon nanotubes are a few examples of nanocarriers which are used extensively. The surface of the nanoparticles is modified or conjugated with the suitable ligands for targetingin order to minimise the opsonization and to prolong the circulation time. Targeted nanoparticulate delivery would mainly be beneficial in diseases like cancer and diseases related to the brain.

In this Special Issue, articles are invited to provide a recent insight into the nanocarriers which are useful for targeted drug delivery.

Prof. Sanjay Garg
Dr. Usha Y Nayak
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Molecules is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • dug delivery
  • targeting
  • nanoparticles
  • functionalization
  • conjugation
  • cancer therapy
  • brain targeting
  • lymphatic targeting
  • hepatic targeting

Published Papers (1 paper)

View options order results:
result details:
Displaying articles 1-1
Export citation of selected articles as:

Review

Open AccessFeature PaperReview Cancer Targeting and Drug Delivery Using Carbon-Based Quantum Dots and Nanotubes
Molecules 2018, 23(2), 378; doi:10.3390/molecules23020378
Received: 19 January 2018 / Revised: 7 February 2018 / Accepted: 9 February 2018 / Published: 10 February 2018
PDF Full-text (4316 KB) | HTML Full-text | XML Full-text
Abstract
Currently cancer treatment is in large part non-specific with respect to treatment. Medication is often harsh on patients, whereby they suffer several undesired side effects as a result. Carbon-based nanoparticles have attracted attention in recent years due to their ability to act as
[...] Read more.
Currently cancer treatment is in large part non-specific with respect to treatment. Medication is often harsh on patients, whereby they suffer several undesired side effects as a result. Carbon-based nanoparticles have attracted attention in recent years due to their ability to act as a platform for the attachment of several drugs and/or ligands. Relatively simple models are often used in cancer research, wherein carbon nanoparticles are conjugated to a ligand that is specific to an overexpressed receptor for imaging and drug delivery in cancer treatment. These carbon nanoparticles confer unique properties to the imaging or delivery vehicle due to their nontoxic nature and their high fluorescence qualities. Chief among the ongoing research within carbon-based nanoparticles emerge carbon dots (C-dots) and carbon nanotubes (CNTs). In this review, the aforementioned carbon nanoparticles will be discussed in their use within doxorubicin and gemcitabine based drug delivery vehicles, as well as the ligand-mediated receptor specific targeted therapy. Further directions of research in current field are also discussed. Full article
(This article belongs to the Special Issue Targeted Drug Delivery and Nanocarriers)
Figures

Planned Papers

The below list represents only planned manuscripts. Some of these manuscripts have not been received by the Editorial Office yet. Papers submitted to MDPI journals are subject to peer-review.

  • Type of the paper: Review
  • Tentative title: Protein Nanocapsules for Antitumoral Therapy
  • Authors: Maria Vallet-Regí, Alejandro Baeza, Maria Rocio Villegas
  • Affiliation: Grupo de Investigación Biomateriales Inteligentes, GIBI-CIBER-BBN, Dept. of Chemistry in Pharmaceutical SciencesFac. Pharmacy-UCM, 28020 Madrid, Spain
  • Title: Design and Efficacy of Polymer-based Nanocarriers for Brain Targeting
  • Corresponding Author: B. A. Aderibigbe (blessingaderibigbe@gmail.com)
  • Affiliation: Department of Chemistry, University of Fort Hare, Alice Campus, Eastern Cape, South Africa.
  • Abstract: The delivery of bioactive agent to the brain is hampered by the blood brain barrier. Several methods of administration of bioactive agents to the brain have been reported to be ineffective, unsafe and expensive. Polymer-based nanocarriers can penetrate the blood brain barrier with reduced side effects and are potential carriers for the delivery of bioactive agents to the brain. Their physicochemical properties play a major role in the brain uptake. This review provides a detailed information of the enhanced therapeutic effects, mechanisms and biological efficacy of polymer-based systems for the delivery of drugs to the brain.
  • Keywords: nanocarriers; brain targeting; polymers; HIV; brain cancer
  • Type of the paper: Review
  • Tentative title:  Intraperitoneal targeting of peritoneal carcinomatosis with tumor homing peptides
  • Authors: Tambet Teesalu
  • Affiliation:  Institute of Biomedicine and Translational Medicine, University of Tartu, Estonia
  • Abstract: Peritoneal carcinomatosis (PC) - the metastatic spread of gynecologic, gastric, and colorectal cancers throughout the peritoneal cavity – is a serious clinical condition with an extremely poor prognosis. Compared to intravenous treatment regimens, intraperitoneal chemotherapy (IPC) can be used to improve therapeutic index of anticancer drugs: to achieve higher local concentration of the drug in the peritoneal malignant tissues and lower systemic exposure. To improve IPC further, it is desirable to develop strategies to extend drug retention time in the peritoneal cavity and to improve drug penetration into the peritoneal tumor nodules. In this review, we will describe preclinical development of active targeting strategies to improve IPC. We will focus on the use of tumor homing peptides to increase the peritoneal tumor binding and penetration of peritoneally-administered free and nanoformulated imaging agents and drugs for improved PC detection and treatment.
Back to Top